If you like biotech stocks, start your due diligen

If you like biotech stocks, start your due diligence on Immune Pharmaceuticals!
IMNP ~ About Immune Pharmaceuticals:
Immune Pharmaceuticals (IMNP) applies a personalized approach to treating and developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune's lead product candidate, bertilimumab, is in phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. Other indications being considered for development include atopic dermatitis, Crohn's disease, severe asthma and NASH (an inflammatory liver disease). Immune recently expanded its portfolio in immuno-dermatology with topical nano-formulated cyclosporine-A for the treatment of psoriasis and atopic dermatitis. Immune's oncology pipeline includes, bispecific antibodies, nanotherapeutics (NanomAbs®), and several mid-to-late stage small molecules. Immune's non-core pipeline includes AmiKet®, a late clinical stage drug candidate for the treatment of neuropathic pain. For more information, visit Immune's website at www.immunepharmaceuticals.com, the content of which is not a part of this press release.

Disclaimer must be read and fully understood ~ ALL POST SHOULD BE CONSIDERED COMPENSATED AWARENESS/MARKETING POSTS. THESE POSTS ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT SOLICITATIONS!